BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) CEO Vimal Mehta sold 5,268 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $2.62, for a total transaction of $13,802.16. Following the sale, the chief executive officer now owns 43,564 shares of the company’s […]
Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 BioXcel.
Analysts Set BioXcel Therapeutics, Inc (NASDAQ:BTAI) Price Target at $16 86 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) saw a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 3,140,000 shares, a decline of 20.9% from the February 29th total of 3,970,000 shares. Currently, 14.6% of the company’s shares are sold short. Based on an […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) was the target of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 3,140,000 shares, a drop of 20.9% from the February 29th total of 3,970,000 shares. Based on an average trading volume of 1,530,000 shares, […]